Free Trial

Silence Therapeutics (SLNCF) 10K Form and Latest SEC Filings 2026

Silence Therapeutics logo
$2.36 0.00 (0.00%)
As of 05/4/2026

Latest Silence Therapeutics SEC Filings & Recent Activity

Silence Therapeutics (OTCMKTS:SLNCF) has submitted 166+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 10-K submitted on March 5, 2026.

Form 4
Silence Therapeutics plc Reports Ownership Change on Feb. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-K
Silence Therapeutics Files Annual Report on Mar. 5, 2026

The 10-K contains Silence Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Silence Therapeutics SEC Filing History

Browse Silence Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
03/05/2026 6:40 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 6:49 AM
Silence Therapeutics (1479615) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/13/2026 5:02 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/09/2026 12:16 PM
Lombard Odier Asset Management (0) USA
Silence Therapeutics (1479615) Subject
Form SCHEDULE 13G/A
01/06/2026 3:15 PM
Lemus David (1717972) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:15 PM
HELLUMS RHONDA LYNETTE (1766456) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:15 PM
Romano Steven J. (1639860) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:15 PM
MCINERNEY TIMOTHY (1226020) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:15 PM
Ede-Golightly James (2048873) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 5:02 PM
Ede-Golightly James (2048873) Reporting
Silence Therapeutics (1479615) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/22/2025 5:03 PM
Ede-Golightly James (2048873) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 5:04 PM
Ross Iain (1307218) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:01 PM
Silence Therapeutics (1479615) Filer
Form 8-K/A
12/22/2025 6:32 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 6:53 AM
Silence Therapeutics (1479615) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 6:38 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/23/2025 6:45 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 5:30 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2025 7:04 AM
Silence Therapeutics (1479615) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/07/2025 6:35 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/04/2025 7:03 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/31/2025 7:43 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/23/2025 1:22 PM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2025 1:58 PM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2025 7:36 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2025 11:31 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 6:00 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2025 9:24 AM
Griffiths Richard Ian (1846370) Filed by
Silence Therapeutics (1479615) Subject
Form SCHEDULE 13D/A
06/25/2025 7:59 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2025 5:46 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 7:06 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2025 10:21 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 7:35 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 5:49 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2025 3:12 PM
MCINERNEY TIMOTHY (1226020) Reporting
Silence Therapeutics (1479615) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/20/2025 3:14 PM
MCINERNEY TIMOTHY (1226020) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2025 5:05 AM
Silence Therapeutics (1479615) Filer
Form DEF 14A
05/16/2025 5:07 AM
Silence Therapeutics (1479615) Filer
Form ARS
05/15/2025 8:02 PM
Redmile Group, LLC (1425738) Filed by
Silence Therapeutics (1479615) Subject
Form SCHEDULE 13G/A
05/08/2025 9:18 AM
Griffiths Richard Ian (1846370) Filed by
Silence Therapeutics (1479615) Subject
Form SCHEDULE 13D/A
05/08/2025 7:10 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2025 7:35 AM
Silence Therapeutics (1479615) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/08/2025 6:08 AM
Griffiths Richard Ian (1846370) Reporting
Silence Therapeutics (1479615) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2025 7:03 AM
Silence Therapeutics (1479615) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2025 7:06 AM
Silence Therapeutics (1479615) Filer
Form PRE 14A
(Data available from 1/1/2016 forward)

Silence Therapeutics SEC Filings - Frequently Asked Questions

Silence Therapeutics (SLNCF) has submitted 166+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 10-K submitted on March 5, 2026. This was the company's annual report for fiscal year 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (OTCMKTS:SLNCF) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners